Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, Nov. 21, 2023. Victoria Klesty | Reuters The insatiable demand for weight loss …
Cue the George Orwell reference. Depending on where you work, there’s a significant chance that artificial intelligence is analyzing your messages on Slack, Microsoft Teams, Zoom and other popular apps. …
The biopharmaceutical sector is expected to offer a safe haven from macroeconomic and earnings concerns ahead of final quarterly results from companies, according to Morgan Stanley. The Wall Street bank …
Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical activity. Michael Siluk …
Medical personnel use a mammogram to examine a woman’s breast for breast cancer. Hannibal Hanschke | dpa | Picture Alliance | Getty Images SAN FRANCISCO — An established but promising …
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. As these new therapies begin treating patients, some investors see better times ahead next year. “We’ve …
Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC. Anna Moneymaker …
For many struggling with obesity, new medications have been “a gift,” as Oprah Winfrey recently described it in declaring she was “done with the shaming.” Investors in drug manufacturers Novo …
George Frey | Bloomberg | Getty Images Weight loss drugs exploded into the public eye this year, and 2024 will bring more change to the evolving market. The drugs skyrocketed …
For many investors, the weight loss drug boom has boosted Danish pharmaceutical giant Novo Nordisk ‘s appeal this year — but one investment bank has reservations. “Over the coming year, …